A phase II study of cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) in high-risk previously untreated patients with CLL [chronic lymphocytic leukaemia].

Trial Profile

A phase II study of cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) in high-risk previously untreated patients with CLL [chronic lymphocytic leukaemia].

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2013

At a glance

  • Drugs Alemtuzumab; Cyclophosphamide; Fludarabine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 10 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Apr 2011 Planned end date changed from 1 Jun 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top